Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation

Despite the effectiveness of endocrine therapies in estrogen receptor positive (ER+) breast cancer, approximately 40% of patients relapse. Previously, we identified the Focal-adhesion kinase canonical pathway as a major contributor of resistance to estrogen deprivation and cellular-sarcoma kinase (c...

Descripción completa

Detalles Bibliográficos
Autores principales: Guest, Stephanie K., Ribas, Ricardo, Pancholi, Sunil, Nikitorowicz-Buniak, Joanna, Simigdala, Nikiana, Dowsett, Mitch, Johnston, Stephen R., Martin, Lesley-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911087/
https://www.ncbi.nlm.nih.gov/pubmed/27308830
http://dx.doi.org/10.1371/journal.pone.0157397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911087/
https://www.ncbi.nlm.nih.gov/pubmed/27308830
http://dx.doi.org/10.1371/journal.pone.0157397

Ejemplares similares